Introduction
Outpatient parenteral antimicrobial therapy (OPAT) is now standard treatment for patients who require intravenous antimicrobials for longer than the few days that they otherwise need to be hospitalized for, and practice guidelines for such treatment have been published. 1 -3 With short hospital stays being the norm, patients treated with parenteral antimicrobials receive a significant proportion of their treatment outside the hospital. The close medical attention that hospitalized patients receive cannot be ensured after patients are discharged from hospital. The benefits of early discharge (including patient satisfaction and decreased costs) may be offset by antimicrobial adverse events or vascular access complications that cause patient distress, result in emergency department or unscheduled physician office visits, or lead to rehospitalizations.
Vancomycin and daptomycin are the two most commonly used antimicrobials for parenteral treatment of Gram-positive bacterial infections. Daptomycin is a relatively new antimicrobial effective for treating infections caused by Gram-positive bacteria. It is at least as effective as oxacillin and vancomycin for treating methicillin-susceptible and methicillin-resistant Staphylococcus aureus infections, respectively. 4 Retrospective studies have found more adverse events with vancomycin than with daptomycin. 5, 6 However, some of these studies are limited by the fact that the patients treated with daptomycin were different from the patients treated with vancomycin. In clinical trials, the overall incidence of adverse events associated with daptomycin has been similar to that for comparator drugs (often including vancomycin). 7 -10 Nevertheless, in clinical practice, there is a widespread perception that patients treated with vancomycin experience more adverse events than patients treated with daptomycin. There are no studies that have directly compared adverse events of these medications when used during OPAT.
The aim of this study was to compare adverse event rates associated with daptomycin and vancomycin during OPAT for patients treated at home, and the healthcare interventions and healthcare utilization resulting from monitoring for and management of complications.
Methods

Setting and study design
The study was a retrospective propensity score-matched cohort study of patients receiving OPAT at home with either daptomycin or vancomycin. The study was conducted at Cleveland Clinic, a large multispecialty tertiary care referral centre. Cleveland Clinic has a large OPAT programme that has been in operation since 1980 and now comprises over 3000 OPAT courses a year. 11 All patients to be discharged on intravenous antimicrobial therapy from Cleveland Clinic require evaluation by a Cleveland Clinic infectious disease staff physician before discharge from hospital. Every OPAT course requires completion of a structured start-of-care form, including orders for weekly laboratory monitoring, by the attending physician at the start of the OPAT course. Data in these forms are the basis of the Cleveland Clinic OPAT registry.
Data sources and data extraction
Sources of data were the Cleveland Clinic OPAT registry and the institution's electronic health record. Data from the latter were collected via structured electronic queries and manual chart review. Collected data were entered in a relational database (Microsoft w Access).
Case ascertainment and inclusion and exclusion criteria
Cases were identified through the Cleveland Clinic OPAT registry. All OPAT courses for vancomycin or daptomycin for patients at least 18 years of age, initiated between 1 July 2007 and 30 June 2010, were screened for inclusion in the study. OPAT courses started in the outpatient setting, OPAT courses lasting ,3 days, OPAT administration anywhere other than home and courses in which the post-discharge antimicrobial management was performed by a non-Cleveland Clinic physician were excluded. Only the first OPAT course per patient was included in the study.
Identification of the matched cohort
For each patient included, the propensity to be treated with daptomycin was calculated. The factors used for calculating the propensity score were a broad range of factors that the infectious disease physicians in our institution felt might directly or indirectly affect a decision to choose between vancomycin and daptomycin for patients who could be treated with either antimicrobial. Factors used for propensity scoring included age, gender, race (Caucasian/African-American/other), body mass index (BMI), payer type (public/private), calendar year, diagnosis category (bone and joint infection, endocarditis or cardiac device infection, other infection), microorganism (S. aureus, coagulase-negative staphylococci, Enterococcus spp., other, no identified pathogen), bacteraemia, diabetes mellitus, coronary artery disease, congestive heart failure, prior stroke, chronic obstructive pulmonary disease (COPD), cirrhosis of the liver, solid organ transplant, haematopoietic stem cell transplant, surgery during hospitalization, all-purpose refined-diagnosis related group (APR-DRG) severity score class, APR-DRG mortality risk class, type of antimicrobial therapy (pathogen-guided or empirical), duration of hospitalization, duration of intensive care unit (ICU) stay, white blood cell count at hospital discharge, serum creatinine at hospital discharge, number of classes of medications at discharge, vascular access device, homecare pharmacy (Cleveland Clinic or other), homecare nursing agency (Cleveland Clinic or other) and anticipated OPAT duration. For each daptomycin-treated patient, propensity score-matched controls were identified from among the patients treated with vancomycin.
Outcomes
The outcomes evaluated were adverse events, healthcare interventions and healthcare utilization during the OPAT course. Adverse events included antimicrobial adverse events and vascular access complications. Healthcare interventions included antimicrobial interventions and vascular access interventions. Healthcare utilization included telephone encounters and emergency department visits. Hospital readmissions were also examined. Outcomes in the daptomycin-treated patients were compared with those in the vancomycin-treated controls.
Definitions
Antimicrobial adverse events included both clinical and laboratory events, and were defined and graded as outlined in the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events. 12 Nephrotoxicity was defined as a 1.5-fold or greater increase in serum creatinine and severity was graded based on the RIFLE criteria proposed by the Acute Dialysis Quality Initiative (ADQI) group. 13 Vascular access complications were defined as venous thrombosis (presence of venous thrombosis documented by venous ultrasound or venous duplex imaging), line infection (positive blood cultures and physician assessment that the patient had a line infection), accidental dislodgement and line malfunction (infusion difficulty requiring emergency department or urgent office visit or resulting in missing at least one dose of medication). Antimicrobial interventions were defined as antimicrobial dosage adjustments, antimicrobial changes and premature antimicrobial discontinuations. Vascular access interventions were defined as catheter manipulation, change or premature removal.
Statistical analysis
The balance of missing data was evaluated between the daptomycin and vancomycin groups. There were some missing data for six of the 29 variables used for propensity scoring. The proportion of data missing for each of these variables ranged from 0.5% to 4.5%. Univariable comparisons of missingness gave no indication to suggest that missingness was more common in one group than the other (Table S1 , available as Supplementary data at JAC Online).
Imputation of missing data was subsequently performed using the R package mice.
14 Imputation was given a seed value of 13 576 and 100 samples were imputed. Logistic regression models were built for all samples using different random values for imputed values, and propensity scores (probability of being treated with daptomycin) were calculated from each model. The mean propensity score from these 100 models was calculated for each patient. This is consistent with suggestions by Mitra and Reiter. 15 Matching for the propensity score was performed using the R package matching. 16 For the purposes of matching, missing values were replaced by the mean of the imputed data (or the mode, for categorical variables) from the 100 imputations performed. The calliper used for matching was the number of standard deviations away from the mean propensity score. The calliper was varied from 0.5 to 1.5 in increments of 0.25, and 1-to-1, 2-to-1, 3-to-1 and 4-to-1 matchings were done. Subjects were matched without replacement. The matched datasets were evaluated using Rubin's Rules 17 to determine the optimum matched cohort. Datasets were also compared using absolute standardized difference plots. Standardized differences of means, variance ratio of propensity scores and variance ratio of residuals under different matching conditions were compared ( Figure S1 , available as Supplementary data at JAC Online). After evaluating these findings in accordance with Rubin's Rules, it was decided that 3-to-1 matching with a calliper of 0.75 provided the best match. The absolute standardized differences for individual variables in the final matched set showed that the groups were well matched ( Figure S2 , available as Supplementary data at JAC Online).
In the matched cohort, adverse event and healthcare utilization rates for daptomycin-treated and vancomycin-treated patients were compared using negative binomial regression models. A sensitivity analysis was performed by doing a 1 : 1 comparison of daptomycin-treated patients with the best propensity score-matched vancomycin-treated control using negative binomial regression models.
Statistical analyses were performed using SAS software (version 9; Cary, NC, USA) and R software (version 2; Vienna, Austria), and we assumed a significance level of 0.05.
Results
Between 1 July 2007 and 30 June 2010, 3279 OPAT courses with daptomycin or vancomycin were prescribed for patients 18 years or older. The study flow is shown in Figure 1 . After exclusions, 1288 patients who received vancomycin or daptomycin during at least one OPAT course were identified. The matching algorithm identified 119 daptomycin-treated patients (with 2518 OPAT days) and 357 vancomycin-treated propensity score-matched controls (with 6649 OPAT days).
Baseline characteristics of included patients
Univariable comparisons for the vancomycin-treated and daptomycin-treated patients for the included patients are presented in Table 1 . The daptomycin-treated patients had a higher burden of comorbid conditions, a higher proportion treated for bacteraemic infection, a higher proportion treated with pathogen-guided therapy as opposed to empirical therapy, higher APR-DRG severity class and mortality risk scores, longer durations of hospitalization and a higher proportion with tunnelled catheters for vascular access, and were discharged on more classes of medications. The predominant microorganism had a disproportionate representation of Enterococcus in the daptomycin-treated patients, and no pathogen identified in the vancomycin-treated patients.
Baseline comparison of matched groups
Univariable comparisons of demographic and clinical characteristics of the two groups in the propensity score-matched cohort are outlined in Table 2 . The only significant difference across the groups was the distribution of predominant microorganism, with Enterococcus disproportionately associated with the daptomycin group and S. aureus disproportionately associated with the vancomycin group. Overall, the mean patient age was 56 years, the most common infection was catheter-associated/ primary bacteraemia (30%), the most common pathogen was S. aureus (38%) and the mean OPAT duration was 19 days.
Comparison of outcomes
Outcomes for the two groups are compared in Rates of vascular access complications, vascular access interventions, telephone encounters and emergency department visits were not different across the two groups. The relative rates changed very little when adjustments were made for the predominant microorganism. The relative rates were similar when a sensitivity analysis was done using the best propensity score-matched control in a 1 : 1 comparison. Table 4 shows the distribution of antimicrobial adverse events. The most commonly encountered adverse events were rash and acute kidney injury. The major driver of the difference in antimicrobial interventions was dose/frequency adjustments, which occurred significantly more frequently in the vancomycin-treated group (Table 5) .
There was no significant difference in overall hospital readmissions (daptomycin 21%, vancomycin 18%) or readmissions for worsening infection/treatment complication (daptomycin 5%, vancomycin 7%). The OPAT course was prematurely stopped on account of antimicrobial adverse events in 6 (5%) and 18 (5%) of the daptomycin-treated and vancomycin-treated patients, respectively.
Discussion
This study shows that patients receiving daptomycin via home infusion had a 60% lower rate of antimicrobial adverse events and an 80% lower rate of antimicrobial interventions than similar patients receiving vancomycin. In absolute terms, patients treated with daptomycin had 4.5 fewer antimicrobial adverse events and required 22.4 fewer antimicrobial interventions per 1000 OPAT days than similar patients treated with vancomycin. The adverse event rates found in our study are of the same order of magnitude as rates noted in previous studies that have examined adverse events in patients receiving OPAT with various antimicrobials. 18 -20 Our study was conducted in an institution with a wellorganized OPAT programme 11 and only included patients receiving treatment at home. The study has several strengths. The organization of our OPAT programme ensures that all patients discharged from hospital on parenteral antimicrobials are included in our OPAT registry and would have thus been screened for the study. Propensity score matching adjusted for the fact that patients treated with daptomycin are often very different from those treated with vancomycin and allowed meaningful comparisons to be made. OPAT is a reasonably safe undertaking, and expected adverse event rates are low. Our large sample size allowed the detection of differences despite small absolute event rates. Laboratory test monitoring of adverse events followed in the programme is along the lines recommended in the Infectious Diseases Society of America (IDSA) practice guidelines Daptomycin and vancomycin OPAT adverse events for OPAT. 2 The specific tests depend on the antimicrobial used. The frequency of monitoring is once a week for most medications. Relative rates of antimicrobial adverse events should be generalizable to other practices that monitor adverse events similarly.
A discordant finding in our study is that despite significantly lower antimicrobial adverse event and antimicrobial intervention rates, telephone encounter rates, though lower in the daptomycin group, were not significantly different. This may have resulted from inconsistent documentation of telephone encounters in the medical record.
The study has its limitations. Being a retrospective study based on data entered in the medical record, this analysis almost certainly underestimated the absolute rates of events overall. There should, however, be little reason for differences between groups, and the relative rates of events between the groups should not have been affected by this limitation. Additionally, every institution or practice has its own approach to managing adverse events. In our institution, patients are typically seen in follow-up in clinic once at the end of therapy. Patients are seen earlier if there are any untoward events. Healthcare intervention and healthcare utilization rates found in our study may not be generalizable to other clinical settings with different practice cultures. Finally, our study only included patients treated at home. The results should not be extrapolated to patients treated in dialysis or infusion centres, or settings such as long-term acute care, rehabilitation or skilled nursing facilities.
The implications of these study findings are that physicians have to decide whether the added costs of an increased burden of adverse events and antimicrobial interventions outweigh the lower antimicrobial cost of vancomycin compared with daptomycin. This study's results should not be interpreted to mean that daptomycin should be preferred over vancomycin for OPAT in all patients. There are many factors that have to be weighed in making such a decision in any individual patient. 2, 3 These factors include, but are not limited to, the infection that is being treated, the MICs of the antimicrobials for the causative pathogen, relative efficacies of the treatment alternatives, the potential for antimicrobial resistance and the consequent burden to the patient and to society, the infusion setting (home or infusion centre), insurance coverage and relevant directs costs to patients. An estimate of the burden of adverse events and antimicrobial interventions, as provided by this study, will help in making a more informed decision.
In conclusion, patients receiving daptomycin via home infusion have significantly fewer antimicrobial adverse events and require significantly fewer antimicrobial interventions than similar patients receiving vancomycin. This knowledge may influence antimicrobial treatment choices for patients who require outpatient parenteral treatment for Gram-positive bacterial infections. Based on negative binomial regression models, to account for over-dispersion in the observed data. Shrestha et al.
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